Skip to content

US · CURX · BIOTECHNOLOGY

Curanex Pharmaceuticals Inc Common Stock (CURX) intrinsic value and stock valuation

$4.41as of 2026-11-21 · Mkt cap 5.53M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Curanex Pharmaceuticals Inc Common Stock DCF and intrinsic value

InvestorsCraft values CURX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CURX’s statements →

Curanex Pharmaceuticals Inc Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Jericho, NY 11753 curanexpharma.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$0.00
20222025
Net income
-$-4.23M
20222025
Free cash flow
-$-10.48M
20232025
Total equity
$11.2M
20232025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$0.00$0.00$0.00$30K
Operating income-$-4.24M-$-370K-$-20K-$-20K
Net income-$-4.23M-$-360K-$-20K-$-20K
EPSd-$-165.88K-$-12.97K-$476.19-$476.19
Operating cash flow-$-10.48M-$-560K-$0.00—
Capital expenditure$0.00$0.00$0.00—
Free cash flow-$-10.48M-$-560K-$0.00—
Total assets$11.6M$520K$70K—
Total debt$350K$0.00$0.00—
Net debt-$-4.63M-$-150K-$-70K—
Total equity$11.2M$500K$60K—
Cash and short-term investments$4.97M$150K$70K—
Income statement
2025202420232022
Revenue$0.00$0.00$0.00$30K
Cost of revenue$0.00$0.00$0.00$20K
Gross profit$0.00$0.00$0.00$0.00
Research and development expenses$2.99M$0.00$0.00$0.00
Selling, general and administrative expenses$1.25M$290K$20K$20K
Other expenses$0.00$70K$0.00$0.00
Operating expenses$4.24M$370K$20K$20K
Cost and expenses$4.24M$370K$20K$50K
Interest income$0.00$0.00$0.00$0.00
Interest expense-$-10K$0.00$0.00$0.00
Depreciation and amortization$80K$0.00$0.00$20K
Ebitda$80K-$-290K-$-20K$0.00
Operating income-$-4.24M-$-370K-$-20K-$-20K
Total other income/expenses, net$10K$0.00$0.00$0.00
Income before tax-$-4.23M-$-360K-$-20K-$-20K
Income tax expense$0.00$0.00$0.00$0.00
Net income-$-4.23M-$-360K-$-20K-$-20K
Weighted average shares outstanding$25.5M$27.8M$42M$42M
Weighted average diluted shares outstanding$25.5M$27.8M$42M$42M
Balance sheet
202520242023
Cash and short-term investments$4.97M$150K$70K
Net receivables$0.00$0.00$0.00
Inventory$0.00$0.00$0.00
Total current assets$11.2M$520K$70K
Property, plant and equipment, net$350K$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00
Total non-current assets$350K$0.00$0.00
Total assets$11.6M$520K$70K
Accounts payable$0.00$10K$0.00
Short-term debt$120K$0.00$0.00
Deferred revenue$0.00$0.00$0.00
Total current liabilities$140K$10K$10K
Long-term debt$220K$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00
Total non-current liabilities$220K$0.00$0.00
Capital lease obligations$120K$0.00$0.00
Total liabilities$360K$10K$10K
Common stock$0.00$0.00$0.00
Retained earnings-$-4.85M-$-620K-$-260K
Accumulated other comprehensive income (loss)$0.00$0.00$0.00
Total equity$11.2M$500K$60K
Total investments$0.00$0.00$0.00
Total debt$350K$0.00$0.00
Net debt-$-4.63M-$-150K-$-70K
Cash flow statement
202520242023
Net income-$-4.23M-$-360K-$-20K
Depreciation and amortization$80K$0.00$0.00
Stock-based compensation$0.00$0.00$0.00
Change in working capital$0.00-$-270K$20K
Accounts receivable$0.00$0.00$0.00
Inventory$0.00$0.00$0.00
Accounts payable-$0.00$10K$0.00
Net cash provided by operating activities-$-10.48M-$-560K-$0.00
Investments in property, plant and equipment$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00
Common stock issued$15.7M$630K$70K
Common stock repurchased$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00
Net cash used for financing activities$15.3M$630K$70K
Net change in cash$4.82M$70K$70K
Cash at end of period$4.97M$150K$70K
Operating cash flow-$-10.48M-$-560K-$0.00
Capital expenditure$0.00$0.00$0.00
Free cash flow-$-10.48M-$-560K-$0.00
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Curanex Pharmaceuticals Inc Common Stock

        Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.

        CEO
        Jun Liu
        Employees
        6
        Beta
        -2.74

        Explore

        Frequently asked questions

        What is the intrinsic value of Curanex Pharmaceuticals Inc Common Stock (CURX)?

        InvestorsCraft does not currently publish an intrinsic value for CURX. How the IC value is calculated.

        Is CURX undervalued?

        InvestorsCraft does not publish an undervaluation signal for CURX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.